London, England, United Kingdom hVIVO appeared to be the Corporate Investor, which was created in 1988. The leading representative office of defined Corporate Investor is situated in the London. The company was established in Europe in United Kingdom.
Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is constantly included in less than 2 deals per year. The important activity for fund was in 2016.
The standard case for the fund is to invest in rounds with 2 partakers. The meaningful sponsors for the fund in investment in the same round are SEEK Group, Johnson & Johnson Innovation.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - United Kingdom. Among the most successful fund investment fields, there are Biotechnology, Health Care. Among the various public portfolio startups of the fund, we may underline Imutex
| Fund Name | Location |
| Armada Credit Partners | Finland, Helsinki, Southern Finland |
| Boshi Zichan Guanli Gufen Co., Ltd | China, Shanghai |
| Boxer Capital | Florida, United States, Windermere |
| Canopy Growth | Canada, Ontario, Smiths Falls |
| China Beststudy Education Group | China, Guangdong, Guangzhou |
| EDP Ventures | Lisboa, Lisbon, Portugal |
| Kaga Electronics | Japan, Tokyo |
| Rheinische Post Mediengruppe | - |
| Zhongjiantou Investment Management | China, Hangzhou, Zhejiang |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Imutex | $19M | 28 Apr 2016 | England | ||
PrEP Biopharm | $28M | 02 Nov 2015 | England |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Imutex | $19M | 28 Apr 2016 | England | ||
PrEP Biopharm | $28M | 02 Nov 2015 | England |
